| 99120-8 |
Oropouche virus Ab.Neut |
Titr |
XXX |
Pt |
SemiQn |
Neut |
|
ACTIVE |
Oropouche virus neutralizing antibody [Titer] in Specimen by Neutralization test |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
99120-8 |
|
Neut |
|
|
Both |
|
|
|
0 |
Oropouche virus NAb Titr Spec Nt |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Conventional virus neutralization test; cVNT; Dilution factor; Dilution Factor (Titer); Microbiology; Misc; Miscellaneous; NAb; NEUTRALIZATION; Neutralization test; NT; Orthobunyaviruses; Other; Point in time; Random; Serum virus neutralization; SmQn; Spec; SVN; Titer; Titered; Titre; To be specified in another part of the message; Ttr; Unspecified; Virus neutralization test; VNT |
2.75 |
2.72 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 99121-6 |
Rift Valley fever virus Ab.Neut |
Titr |
XXX |
Pt |
SemiQn |
Neut |
|
ACTIVE |
Rift valley fever virus neutralizing antibody [Titer] in Specimen by Neutralization test |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
99121-6 |
|
Neut |
|
|
Both |
|
|
|
0 |
RVFV NAb Titr Spec Nt |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Bunyavirus; Conventional virus neutralization test; cVNT; Dilution factor; Dilution Factor (Titer); Microbiology; Misc; Miscellaneous; NAb; NEUTRALIZATION; Neutralization test; NT; Other; Point in time; Random; Rift valley fever; RVFV; Serum virus neutralization; SmQn; Spec; SVN; Titer; Titered; Titre; To be specified in another part of the message; Ttr; Unspecified; Virus neutralization test; VNT |
2.75 |
2.72 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 99122-4 |
Bwamba virus Ab.Neut |
Titr |
XXX |
Pt |
SemiQn |
Neut |
|
ACTIVE |
Bwamba virus neutralizing antibody [Titer] in Specimen by Neutralization test |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
99122-4 |
|
Neut |
|
|
Both |
|
|
|
0 |
Bwamba virus NAb Titr Spec Nt |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Conventional virus neutralization test; cVNT; Dilution factor; Dilution Factor (Titer); Microbiology; Misc; Miscellaneous; NAb; NEUTRALIZATION; Neutralization test; NT; Orthobunyaviruses; Other; Point in time; Random; Serum virus neutralization; SmQn; Spec; SVN; Titer; Titered; Titre; To be specified in another part of the message; Ttr; Unspecified; Virus neutralization test; VNT |
2.75 |
2.72 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 99123-2 |
Heartland banyangvirus Ab.Neut |
Titr |
XXX |
Pt |
SemiQn |
Neut |
|
ACTIVE |
Heartland banyangvirus neutralizing antibody [Titer] in Specimen by Neutralization test |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
99123-2 |
|
Neut |
|
|
Both |
|
|
|
0 |
HRTV NAb Titr Spec Nt |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Bhanja virus serocomplex; Conventional virus neutralization test; cVNT; Dilution factor; Dilution Factor (Titer); Heartland virus; HRTV; lone star tick; Microbiology; Misc; Miscellaneous; NAb; NEUTRALIZATION; Neutralization test; NT; Other; Phleboviruses; Point in time; Random; Serum virus neutralization; SmQn; Spec; SVN; Titer; Titered; Titre; To be specified in another part of the message; Ttr; Unspecified; Virus neutralization test; VNT |
2.75 |
2.72 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 99124-0 |
Tick-borne encephalitis virus Ab.Neut |
Titr |
XXX |
Pt |
SemiQn |
Neut |
|
ACTIVE |
Tick-borne encephalitis virus neutralizing antibody [Titer] in Specimen by Neutralization test |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
99124-0 |
|
Neut |
|
|
Both |
|
|
|
0 |
TBEV NAb Titr Spec Nt |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Conventional virus neutralization test; cVNT; Dilution factor; Dilution Factor (Titer); Enc; Enceph; Encephalomyelitis; Microbiology; Misc; Miscellaneous; NAb; NEUTRALIZATION; Neutralization test; NT; Other; Point in time; Random; Serum virus neutralization; SmQn; Spec; SVN; TBEV; TBEV Ab; Tick borne encephalitis virus; Titer; Titered; Titre; To be specified in another part of the message; Ttr; Unspecified; Virus neutralization test; VNT |
2.75 |
2.72 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 99125-7 |
Bunyamwera virus Ab.Neut |
Titr |
XXX |
Pt |
SemiQn |
Neut |
|
ACTIVE |
Bunyamwera virus neutralizing antibody [Titer] in Specimen by Neutralization test |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
99125-7 |
|
Neut |
|
|
Both |
|
|
|
0 |
Bunyamwera virus NAb Titr Spec Nt |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Conventional virus neutralization test; cVNT; Dilution factor; Dilution Factor (Titer); Microbiology; Misc; Miscellaneous; NAb; NEUTRALIZATION; Neutralization test; NT; Orthobunyaviruses; Other; Point in time; Random; Serum virus neutralization; SmQn; Spec; SVN; Titer; Titered; Titre; To be specified in another part of the message; Ttr; Unspecified; Virus neutralization test; VNT |
2.75 |
2.72 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 99126-5 |
NOTCH1 gene targeted mutation analysis |
Prid |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
NOTCH1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
99126-5 |
|
Molgen |
|
|
Both |
|
|
|
0 |
NOTCH1 Mut Anl Bld/T |
|
|
|
N |
|
AOS5; AOVD1; Blood; hN1; Identity or presence; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; Nominal; notch 1; PCR; Point in time; Random; TAN1; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 99127-3 |
BIRC3 gene targeted mutation analysis |
Prid |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
BIRC3 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
99127-3 |
|
Molgen |
|
|
Both |
|
|
|
0 |
BIRC3 gene Mut Anl Bld/T |
|
|
|
N |
|
Blood; Identity or presence; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; Nominal; PCR; Point in time; Random; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 99128-1 |
PLCG2 gene targeted mutation analysis |
Prid |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
PLCG2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
99128-1 |
|
Molgen |
|
|
Both |
|
|
|
0 |
PLCG2 gene Mut Anl Bld/T |
|
|
|
N |
|
Blood; Identity or presence; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; Nominal; PCR; Point in time; Random; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 99129-9 |
SF3B1 gene targeted mutation analysis |
Prid |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
SF3B1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
99129-9 |
|
Molgen |
|
|
Both |
|
|
|
0 |
SF3B1 gene Mut Anl Bld/T |
|
|
|
N |
|
Blood; Hsh155; Identity or presence; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; Nominal; PCR; Point in time; PRP10; PRPF10; Random; SAP155; SF3b155; splicing factor 3b subunit 1; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 9913-5 |
P' wave amplitude.lead AVF |
Elpot |
Heart |
Pt |
Qn |
EKG |
|
ACTIVE |
P' wave amplitude in lead AVF |
|
MIN |
DefinitionDescription |
|
|
mV |
|
|
|
|
|
|
EKG.MEAS |
|
9913-5 |
|
EKG |
|
|
Observation |
|
|
|
0 |
P' wave Amp L-AVF |
|
|
|
Y |
|
Cardiac; Cardio; Cardiology; ECG; EKG.MEASUREMENTS; Electrical potential; Electrocardiogram; Electrocardiograph; Heart Disease; Hrt; P prime; P wave; P' wave Amp L-AVF; P wave Amp L-AVF; Painter's colic; PB; Plumbism; Point in time; QNT; Quan; Quant; Quantitative; Random; Voltage |
2.48 |
1.0i |
|
|
|
|
|
|
|
mV |
|
|
|
0 |
| 99130-7 |
Outcome and assessment information set (OASIS) form - version E |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
Outcome and assessment information set (OASIS) form - version E during assessment period [CMS Assessment] |
|
PANEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
99130-7 |
|
CMS Assessment |
|
|
Order |
|
|
|
0 |
|
|
|
|
N |
|
Centers for Medicare and Medicaid Assessment; Form version; Outcome and assessment information set; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.77 |
2.72 |
|
Convenience group |
|
|
|
|
|
|
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; |
0 |
| 99131-5 |
Outcome and assessment information set (OASIS) form - version E - Start of Care |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
Outcome and assessment information set (OASIS) form - version E - Start of Care during assessment period [CMS Assessment] |
|
PANEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
99131-5 |
|
CMS Assessment |
|
|
Order |
|
|
|
0 |
|
|
|
|
N |
|
Centers for Medicare and Medicaid Assessment; Form version; Outcome and assessment information set; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Started; Survey |
2.77 |
2.72 |
|
Panel |
|
|
|
|
|
|
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; |
0 |
| 99132-3 |
OASIS E - Administrative information - SOC |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
OASIS E - Administrative information - SOC during assessment period [CMS Assessment] |
|
PANEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
99132-3 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
N |
|
Admin info; Centers for Medicare and Medicaid Assessment; OASIS E - Admin Info - SOC; Outcome and assessment information set; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.8 |
2.72 |
|
Organizer |
|
|
|
|
|
|
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; |
0 |
| 99133-1 |
Near convergence break |
InvLen |
Eye |
Pt |
Qn |
Phoropter |
|
ACTIVE |
Near convergence break by Phoropter |
|
ADD |
DefinitionDescription |
|
|
diopter |
|
|
|
|
|
|
EYE.REFRACTION |
|
99133-1 |
|
Phoropter |
|
|
Observation |
|
|
|
0 |
Near con break by Phoropter |
|
|
|
N |
|
by Phoropter; EYE.REFRACTION; Eyeball; Inverse Length; Near con break; Occular; Oculis; Ophthalmologic; Optic globe; Point in time; QNT; Quan; Quant; Quantitative; Random; Vision; Visual |
2.72 |
2.72 |
|
|
|
|
|
|
|
[diop] |
|
|
|
0 |
| 99134-9 |
You or your families' health is affected by environmental conditions at home |
Find |
^Patient |
Pt |
Ord |
|
|
ACTIVE |
You or your families' health is affected by environmental conditions at home |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.SDOH |
|
99134-9 |
|
|
|
|
Observation |
|
|
|
0 |
|
|
|
|
N |
|
Finding; Findings; Ordinal; Point in time; QL; Qual; Qualitative; Random; Screen; Survey |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 99135-6 |
Environmental conditions in the home that affect you or your families' health |
Find |
^Patient |
Pt |
Nom |
|
|
ACTIVE |
Environmental conditions in the home that affect you or your families' health |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.SDOH |
|
99135-6 |
|
|
|
|
Observation |
|
|
|
0 |
|
|
|
|
N |
|
Finding; Findings; Nominal; Point in time; Random; Survey |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 99136-4 |
Rabies virus Ab.IgM |
Titr |
XXX |
Pt |
SemiQn |
IF |
|
ACTIVE |
Rabies virus IgM Ab [Titer] in Specimen by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
99136-4 |
|
IF |
|
|
Both |
|
|
|
0 |
RABV IgM Titr Spec IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin M; Infectious Disease; InfectiousDisease; Lyssavirus; Microbiology; Misc; Miscellaneous; Other; Point in time; Rabies; RABV; Random; SmQn; Spec; Time Resolved Fluorescence; Titer; Titered; Titre; To be specified in another part of the message; TRF; Ttr; Unspecified |
2.75 |
2.72 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 99137-2 |
Rabies virus Ab.IgG |
Titr |
XXX |
Pt |
SemiQn |
IF |
|
ACTIVE |
Rabies virus IgG Ab [Titer] in Specimen by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
99137-2 |
|
IF |
|
|
Both |
|
|
|
0 |
RABV IgG Titr Spec IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Lyssavirus; Microbiology; Misc; Miscellaneous; Other; Point in time; Rabies; RABV; Random; SmQn; Spec; Time Resolved Fluorescence; Titer; Titered; Titre; To be specified in another part of the message; TRF; Ttr; Unspecified |
2.75 |
2.72 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 99138-0 |
OASIS E - Hearing, speech, and vision - SOC |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
OASIS E - Hearing, speech, and vision - SOC during assessment period [CMS Assessment] |
|
PANEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
99138-0 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
N |
|
Centers for Medicare and Medicaid Assessment; Outcome and assessment information set; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.8 |
2.72 |
|
Organizer |
|
|
|
|
|
|
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; |
0 |
| 99139-8 |
Sjogrens syndrome-A extractable nuclear 52kD Ab |
ACnc |
Ser |
Pt |
Qn |
Line blot |
|
ACTIVE |
Sjogrens syndrome-A extractable nuclear 52kD Ab [Units/volume] in Serum by Line blot |
|
ADD |
DefinitionDescription |
|
|
arb U/mL |
|
|
|
|
|
|
SERO |
|
99139-8 |
|
Line blot |
|
|
Both |
|
|
|
0 |
ENA SS-A 52kD Ab Ser Line blot-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; ENA; ENA SS-A; ENA SS-A 52kD; Nuc; Point in time; QNT; Quan; Quant; Quantitative; Random; Ro; Ro AB; Serology; Serum; Sjogren; SR; SS; SSA; SS-A |
2.72 |
2.72 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 9914-3 |
P' wave amplitude.lead AVL |
Elpot |
Heart |
Pt |
Qn |
EKG |
|
ACTIVE |
P' wave amplitude in lead AVL |
|
MIN |
DefinitionDescription |
|
|
mV |
|
|
|
|
|
|
EKG.MEAS |
|
9914-3 |
|
EKG |
|
|
Observation |
|
|
|
0 |
P' wave Amp L-AVL |
|
|
|
Y |
|
Cardiac; Cardio; Cardiology; ECG; EKG.MEASUREMENTS; Electrical potential; Electrocardiogram; Electrocardiograph; Heart Disease; Hrt; P prime; P wave; P' wave Amp L-AVL; P wave Amp L-AVL; Painter's colic; PB; Plumbism; Point in time; QNT; Quan; Quant; Quantitative; Random; Voltage |
2.48 |
1.0i |
|
|
|
|
|
|
|
mV |
|
|
|
0 |
| 99140-6 |
OASIS E - Cognitive Patterns - SOC, ROC, DC |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
OASIS E - Cognitive Patterns - SOC, ROC, DC during assessment period [CMS Assessment] |
|
PANEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
99140-6 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
N |
|
Centers for Medicare and Medicaid Assessment; Outcome and assessment information set; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.8 |
2.72 |
|
Organizer |
|
|
|
|
|
|
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; |
0 |
| 99142-2 |
OASIS E - Health Conditions - SOC, ROC |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
OASIS E - Health Conditions - SOC, ROC during assessment period [CMS Assessment] |
|
PANEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
99142-2 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
N |
|
Centers for Medicare and Medicaid Assessment; Outcome and assessment information set; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.8 |
2.72 |
|
Organizer |
|
|
|
|
|
|
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; |
0 |
| 99143-0 |
OASIS E - Special Treatment, Procedures, and Programs - SOC |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
OASIS E - Special Treatment, Procedures, and Programs - SOC during assessment period [CMS Assessment] |
|
PANEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
99143-0 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
N |
|
Centers for Medicare and Medicaid Assessment; Outcome and assessment information set; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey; Tx |
2.8 |
2.72 |
|
Organizer |
|
|
|
|
|
|
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; |
0 |
